NervGen Pharma Corp remains stable amidst a lack of recent news.
This week, NervGen Pharma Corp (NGEN.V) saw no change in its stock price, closing at C$5.15. Despite a challenging year-to-date performance of -35.06%, the stock has maintained consistent trading volume, exceeding its 20-day average.
Investor takeaway: While NervGen's stock hasn't moved significantly this week, investors should keep an eye on the company's recent advancements in clinical studies and financial updates as potential indicators of future performance.
Advertisement
NervGen Pharma Corp
NGEN.V
NGEN.V
NervGen Pharma Corp
WealthAwesomeMarket cap
$407.94M
52W high
$8.49
52W low
$2.57
1W change
+0.00%
Beta
0.86
Analyst Price Targets
Based on analyst covering NGEN
Wall Street analysts forecast NGEN stock price to rise 45.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.48
+45.3% Upside
Current Price
C$5.15
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on NGEN's historical volatility
30-Day Vol
61.5%
Annualized
90-Day Vol
82.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$4.31
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$4.85 | C$3.92 โ C$6.00 |
| 60 trading days | C$4.57 | C$3.39 โ C$6.17 |
| 90 trading days | C$4.31 | C$2.98 โ C$6.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$5.15: NervGen's Current Stock Price
The stock has traded within a 52-week range of C$2.57 to C$8.49, showing substantial potential for recovery if positive developments occur.
Bull case
The recent FDA Fast Track designation for NVG-291 could speed up the drug's development and market entry, which might enhance NervGen's valuation.
Bear case
The company's significant net loss and the absence of recent news could raise concerns about its financial health and operational progress.
Current Price Action
NervGen Pharma Corp's stock closed at C$5.15 this week, unchanged from the previous trading session. The stock's year-to-date performance reflects a decline of 35.06%, which may worry investors seeking stability.
Recent Developments
Advertisement
Despite the lack of major news this week, NervGen has attracted attention for its FDA Fast Track designation received on October 23, 2023, for NVG-291, a treatment aimed at spinal cord injury. This designation could expedite the development process, offering hope for both the company and its investors.
Technical Picture
NervGen's stock is currently trading below its 50-day moving average of C$6.19, indicating a 16.8% decline, while it is above its 200-day moving average of C$4.60, showing a 12.0% increase. The stock has a beta of 0.86, suggesting lower volatility compared to the market. The shares are trading in the middle of their 52-week range of C$2.57 to C$8.49, with recent trading volume at 66,939 shares, which is 1.37 times the 20-day average volume of 49,025 shares.
Insider Activity
There are no recent insider transactions reported for NervGen Pharma Corp, which may indicate stability among its leadership during this period of stock price stagnation.
Price Action Summary
As of the last close, NervGen Pharma Corp remains at C$5.15, reflecting no change in price for the day. Investors should monitor the company's developments closely, as any news could significantly impact future price movements.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
